000739 普洛药业
已收盘 02-09 15:00:00
资讯
新帖
简况
股市必读：普洛药业（000739）2月5日董秘有最新回复
证券之星 · 02-06
股市必读：普洛药业（000739）2月5日董秘有最新回复
普洛药业：CDMO项目数持续保持较快增长
证券之星 · 02-05
普洛药业：CDMO项目数持续保持较快增长
普洛药业（000739）披露对下属公司担保进展公告，1月30日股价下跌4.13%
证券之星 · 01-30
普洛药业（000739）披露对下属公司担保进展公告，1月30日股价下跌4.13%
普洛药业（000739）披露签署战略合作框架协议，1月28日股价下跌1.88%
证券之星 · 01-28
普洛药业（000739）披露签署战略合作框架协议，1月28日股价下跌1.88%
普洛药业最新公告：与德睿智药签订战略合作框架协议
证券之星 · 01-27
普洛药业最新公告：与德睿智药签订战略合作框架协议
股市必读：普洛药业（000739）1月26日董秘有最新回复
证券之星 · 01-27
股市必读：普洛药业（000739）1月26日董秘有最新回复
股市必读：普洛药业（000739）1月14日董秘有最新回复
证券之星 · 01-15
股市必读：普洛药业（000739）1月14日董秘有最新回复
普洛药业：创新药索法地尔III期临床试验已终止
证券之星 · 01-14
普洛药业：创新药索法地尔III期临床试验已终止
普洛药业最新公告：控股股东之一致行动人拟0.6亿元-1.2亿元增持公司股份
证券之星 · 01-13
普洛药业最新公告：控股股东之一致行动人拟0.6亿元-1.2亿元增持公司股份
异动快报：普洛药业（000739）1月13日10点12分触及涨停板
证券之星 · 01-13
异动快报：普洛药业（000739）1月13日10点12分触及涨停板
股市必读：普洛药业（000739）1月9日董秘有最新回复
证券之星 · 01-12
股市必读：普洛药业（000739）1月9日董秘有最新回复
普洛药业：CDMO业务成业绩增长主引擎
证券之星 · 01-09
普洛药业：CDMO业务成业绩增长主引擎
普洛药业(000739.SZ)与西安新通签署战略合作框架协议
智通财经 · 01-06
普洛药业(000739.SZ)与西安新通签署战略合作框架协议
股市必读：普洛药业（000739）1月5日董秘有最新回复
证券之星 · 01-06
股市必读：普洛药业（000739）1月5日董秘有最新回复
普洛药业（000739）披露关于回购公司股份的进展公告，1月5日股价上涨0.25%
证券之星 · 01-05
普洛药业（000739）披露关于回购公司股份的进展公告，1月5日股价上涨0.25%
每周股票复盘：普洛药业（000739）担保余额达37.57亿
证券之星 · 01-03
每周股票复盘：普洛药业（000739）担保余额达37.57亿
普洛药业（000739）披露对下属公司担保进展公告，12月30日股价上涨0.62%
证券之星 · 2025-12-30
普洛药业（000739）披露对下属公司担保进展公告，12月30日股价上涨0.62%
普洛药业（000739）披露回购股份比例达到1%的进展公告，12月24日股价下跌0.42%
证券之星 · 2025-12-24
普洛药业（000739）披露回购股份比例达到1%的进展公告，12月24日股价下跌0.42%
普洛药业（000739）披露获得药品注册证书，12月23日股价上涨0.66%
中金财经 · 2025-12-23
普洛药业（000739）披露获得药品注册证书，12月23日股价上涨0.66%
普洛药业(000739.SZ)：磷酸奥司他韦干混悬剂获得药品注册证书
智通财经 · 2025-12-23
普洛药业(000739.SZ)：磷酸奥司他韦干混悬剂获得药品注册证书
加载更多
公司概况
公司名称：
普洛药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-09
主营业务：
普洛药业股份有限公司的主营业务是原料药中间体、创新药研发生产服务（CDMO）、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品是头孢系列、青霉素系列、精神类系列、心脑血管类系列、兽药原料药中间体系列、研发服务、商业化人用药项目、商业化兽药项目、其他项目、抗感染类、心脑血管类、精神类、抗肿瘤类。
发行价格：
5.70
{"stockData":{"symbol":"000739","market":"SZ","secType":"STK","nameCN":"普洛药业","latestPrice":18.75,"timestamp":1770620610000,"preClose":18.79,"halted":0,"volume":6642488,"delay":0,"changeRate":-0.0021,"floatShares":1158000000,"shares":1158000000,"eps":0.7439,"marketStatus":"已收盘","change":-0.04,"latestTime":"02-09 15:00:00","open":18.96,"high":19.29,"low":18.66,"amount":125000000,"amplitude":0.0335,"askPrice":18.76,"askSize":66,"bidPrice":18.75,"bidSize":57,"shortable":0,"etf":0,"ttmEps":0.7439,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770687000000},"marketStatusCode":5,"adr":0,"adjPreClose":18.79,"symbolType":"stock","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":20.67,"lowLimit":16.91,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1158443576,"isCdr":false,"pbRate":3.36,"roa":"--","peRate":25.205001,"roe":"10.21%","epsLYR":0.8864,"committee":-0.260067,"marketValue":21721000000,"turnoverRate":0.0057,"status":1,"floatMarketCap":21713000000},"requestUrl":"/m/hq/s/000739","defaultTab":"news","newsList":[{"id":"2609883615","title":"股市必读：普洛药业（000739）2月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609883615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609883615?lang=zh_cn&edition=full","pubTime":"2026-02-06 01:15","pubTimestamp":1770311711,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，普洛药业报收于18.8元，下跌0.95%，换手率0.67%，成交量7.76万手，成交额1.46亿元。请广大投资者以公司披露的公告为准，谨慎分析判断，注意投资风险。来自交易信息汇总：散户资金净流入104.02万元，表明散户情绪相对稳定。交易信息汇总资金流向2月5日主力资金净流出1526.9万元；游资资金净流入1422.88万元；散户资金净流入104.02万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000739","BK0060"],"gpt_icon":0},{"id":"2609329831","title":"普洛药业：CDMO项目数持续保持较快增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2609329831","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609329831?lang=zh_cn&edition=full","pubTime":"2026-02-05 15:15","pubTimestamp":1770275725,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业02月05日在投资者关系平台上答复投资者关心的问题。近年来，公司CDMO项目数持续保持较快增长，且逐渐进入商业化生产阶段，有助于CDMO产能利用率的回升；但公司CDMO项目与产能涉及多个子公司、众多生产线，部分产线的生产旺盛并不完全代表公司整体业务情况，也不构成对公司经营业绩的预期指引。请广大投资者以公司披露的公告为准，谨慎分析判断，注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500018994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0188","000739"],"gpt_icon":0},{"id":"2607041104","title":"普洛药业（000739）披露对下属公司担保进展公告，1月30日股价下跌4.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607041104","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607041104?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:36","pubTimestamp":1769783780,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，普洛药业报收于18.36元，较前一交易日下跌4.13%，最新总市值为212.69亿元。该股当日开盘18.98元，最高19.17元，最低18.19元，成交额达2.18亿元，换手率为1.01%。近日，普洛药业披露《关于对下属公司担保的进展公告》。截至目前，公司对上述子公司的担保余额分别为80,000万元、157,500万元、37,058万元。本次担保后，公司对下属公司担保余额为369,638万元，占2024年度经审计净资产的54.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0239","BK0188","BK0060"],"gpt_icon":0},{"id":"2606791211","title":"普洛药业（000739）披露签署战略合作框架协议，1月28日股价下跌1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606791211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606791211?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:35","pubTimestamp":1769592952,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，普洛药业报收于18.76元，较前一交易日下跌1.88%，最新总市值为217.32亿元。该股当日开盘19.12元，最高19.17元，最低18.53元，成交额达2.27亿元，换手率为1.05%。近日，普洛药业股份有限公司与杭州德睿智药科技有限公司签署《战略合作框架协议》，双方将在创新药研发与外包定制生产领域开展长期合作。本次签约对公司本年度经营业绩无重大影响，未来影响将视具体项目实施情况而定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800030306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0239","BK0188","BK0060"],"gpt_icon":0},{"id":"2606207237","title":"普洛药业最新公告：与德睿智药签订战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2606207237","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606207237?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:50","pubTimestamp":1769507430,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司与杭州德睿智药科技有限公司签订《战略合作框架协议》，结成战略合作伙伴，开展CDMO项目的长期合作。该协议不涉及实质性交易，不构成关联交易或重大资产重组。对公司本年度经营业绩不构成重大影响，对未来年度经营业绩的影响将视具体项目协议和实施情况而定。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700030337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0060","000739"],"gpt_icon":0},{"id":"2606751240","title":"股市必读：普洛药业（000739）1月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606751240","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606751240?lang=zh_cn&edition=full","pubTime":"2026-01-27 02:10","pubTimestamp":1769451022,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，普洛药业报收于19.36元，上涨4.65%，换手率1.71%，成交量19.83万手，成交额3.79亿元。董秘最新回复投资者： 董秘，您好！公司的创新药注射用索法地尔的III期临床试验，基于临床研究进展及后续研发投入等因素的综合评估，已于2024年终止。公司暂无在原有研发基础上重新启动临床试验的计划。当日关注点来自交易信息汇总：1月26日主力资金净流入812.06万元，游资积极介入推升市场热度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0188","000739","BK0239"],"gpt_icon":0},{"id":"2603455776","title":"股市必读：普洛药业（000739）1月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603455776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603455776?lang=zh_cn&edition=full","pubTime":"2026-01-15 01:20","pubTimestamp":1768411217,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，普洛药业报收于17.55元，下跌1.35%，换手率2.87%，成交量33.27万手，成交额5.8亿元。公司拟于2026年3月20日披露2025年年度报告，敬请关注公告。来自公司公告汇总：控股股东一致行动人单日增持公司股份0.14%，并披露未来六个月内拟累计增持金额不低于6000万元且不超过1.2亿元。本次权益变动后，控股股东及其一致行动人合计持股比例达52.03%，触及1%整数倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500000931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0188","000739"],"gpt_icon":0},{"id":"2603769990","title":"普洛药业：创新药索法地尔III期临床试验已终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769990","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603769990?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:21","pubTimestamp":1768382474,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，公司目前的创新药索法地尔进衣如何？请详细介绍，谢谢！普洛药业回复：投资者您好！公司的创新药注射用索法地尔的 III 期临床试验，基于临床研究进展及后续研发投入等因素的综合评估，已于2024年终止，详见公司公告（公告编号：2024-02）。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400028961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","000739","BK0188","BK0060","BK1161","06978","BK0239","159992"],"gpt_icon":0},{"id":"2603685787","title":"普洛药业最新公告：控股股东之一致行动人拟0.6亿元-1.2亿元增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603685787","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603685787?lang=zh_cn&edition=full","pubTime":"2026-01-13 19:49","pubTimestamp":1768304969,"startTime":"0","endTime":"0","summary":"普洛药业(000739.SZ)公告称，公司控股股东之一致行动人东阳市横店禹山运动休闲有限公司1月13日以集中竞价交易方式增持公司股份165.35万股，占公司总股本的0.14%，增持金额共计2869.6万元。禹山运动计划自1月13日起6个月内，以自有资金或自筹资金0.6亿元—1.2亿元（包含已增持的2869.6万元）通过集中竞价交易方式增持公司股份。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300037125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000739","BK0060"],"gpt_icon":0},{"id":"2603575929","title":"异动快报：普洛药业（000739）1月13日10点12分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575929?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:15","pubTimestamp":1768270526,"startTime":"0","endTime":"0","summary":"证券之星1月13日盘中消息，10点12分普洛药业触及涨停板。其所属行业化学制药目前上涨。领涨股为尔康制药。该股为减肥药，创新药，合成生物概念热股，当日减肥药概念上涨4.18%，创新药概念上涨3.28%，合成生物概念上涨2.69%。1月12日的资金流向数据方面，主力资金净流出1110.54万元，占总成交额8.05%，游资资金净流入1054.19万元，占总成交额7.65%，散户资金净流入56.35万元，占总成交额0.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300011023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","000739","BK0188"],"gpt_icon":0},{"id":"2602550506","title":"股市必读：普洛药业（000739）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602550506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602550506?lang=zh_cn&edition=full","pubTime":"2026-01-12 03:32","pubTimestamp":1768159929,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，普洛药业报收于16.37元，上涨0.43%，换手率0.61%，成交量7.06万手，成交额1.15亿元。来自公司公告汇总：普洛药业完成2025年第二次股份回购，累计回购22,090,000股，占总股本1.91%，回购金额达3.6亿元上限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200001488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0239","BK0060","BK0188"],"gpt_icon":0},{"id":"2602375996","title":"普洛药业：CDMO业务成业绩增长主引擎","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375996","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602375996?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:48","pubTimestamp":1767962927,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业01月09日在投资者关系平台上答复投资者关心的问题。公司股价受宏观环境、政策形势、行业周期和经营业绩等多种因素影响，近期公司股价较为平稳。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900037994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000739","BK0239","BK0188"],"gpt_icon":0},{"id":"2601867574","title":"普洛药业(000739.SZ)与西安新通签署战略合作框架协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2601867574","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601867574?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:27","pubTimestamp":1767688060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)公告，公司作为乙方与西安新通药物研究股份有限公司(简称“西安新通”、甲方)近日签订了《战略合作框架协议》，旨在开展创新药研发与外包定制生产项目(“CDMO项目”)的长期合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"普洛药业(000739.SZ)与西安新通签署战略合作框架协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0239","000739","BK0188"],"gpt_icon":0},{"id":"2601832380","title":"股市必读：普洛药业（000739）1月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601832380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601832380?lang=zh_cn&edition=full","pubTime":"2026-01-06 04:23","pubTimestamp":1767644588,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，普洛药业报收于16.31元，上涨0.25%，换手率0.65%，成交量7.5万手，成交额1.22亿元。公司拟于2026年3月20日披露2025年年度报告，请及时关注。来自公司公告汇总：截至2025年12月31日，普洛药业已回购股份20,370,000股，占总股本的1.76%，成交总金额达3.32亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600003274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000739","BK0060"],"gpt_icon":0},{"id":"2601000673","title":"普洛药业（000739）披露关于回购公司股份的进展公告，1月5日股价上涨0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000673?lang=zh_cn&edition=full","pubTime":"2026-01-05 18:14","pubTimestamp":1767608065,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，普洛药业报收于16.31元，较前一交易日上涨0.25%，最新总市值为188.94亿元。该股当日开盘16.25元，最高16.32元，最低16.11元，成交额达1.22亿元，换手率为0.65%。截至2025年12月31日，已回购股份20,370,000股，占总股本的1.76%，最高成交价16.85元/股，最低成交价15.71元/股，成交总金额332,025,552.50元。回购符合相关规定，后续将按计划继续实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500028065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000739","BK0239","BK0188","BK0060"],"gpt_icon":0},{"id":"2600067186","title":"每周股票复盘：普洛药业（000739）担保余额达37.57亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067186","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067186?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:55","pubTimestamp":1767380110,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，普洛药业报收于16.27元，较上周的16.4元下跌0.79%。本周，普洛药业12月29日盘中最高价报16.46元。普洛药业当前最新总市值188.48亿元，在化学制药板块市值排名25/150，在两市A股市值排名1044/5181。本周关注点公司公告汇总：普洛药业为子公司提供2.488亿元担保，累计担保余额达37.57亿元，占净资产55.73%。截至目前，公司对下属子公司的担保余额为375,738万元，占2024年度经审计净资产的55.73%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","000739","BK0239"],"gpt_icon":0},{"id":"2595718047","title":"普洛药业（000739）披露对下属公司担保进展公告，12月30日股价上涨0.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595718047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595718047?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:37","pubTimestamp":1767105433,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，普洛药业报收于16.27元，较前一交易日上涨0.62%，最新总市值为188.48亿元。该股当日开盘16.11元，最高16.31元，最低16.05元，成交额达7155.37万元，换手率为0.38%。近日，普洛药业发布关于对下属公司担保的进展公告。上述担保事项已履行相关审议程序，属于公司2024年年度股东大会授权的71亿元担保额度范围内。截至目前，公司对下属子公司的担保余额为375,738万元，占2024年度经审计净资产的55.73%，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0060","000739"],"gpt_icon":0},{"id":"2593470022","title":"普洛药业（000739）披露回购股份比例达到1%的进展公告，12月24日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593470022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593470022?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:38","pubTimestamp":1766587105,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，普洛药业报收于16.65元，较前一交易日下跌0.42%，最新总市值为192.88亿元。该股当日开盘16.7元，最高16.8元，最低16.43元，成交额达1.04亿元，换手率为0.54%。公司近日发布公告称，普洛药业股份有限公司于2025年11月18日召开董事会审议通过回购股份方案，拟使用自有资金及金融机构贷款通过集中竞价方式回购股份，用于股权激励或员工持股计划。本次回购符合方案及相关法规要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400041276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000739","BK0060","BK0188"],"gpt_icon":0},{"id":"2593499995","title":"普洛药业（000739）披露获得药品注册证书，12月23日股价上涨0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593499995","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593499995?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:13","pubTimestamp":1766484790,"startTime":"0","endTime":"0","summary":"h2,h3,h4{padding: 10px 0;font-size: 16px;line-height: 30px;color:#262626;font-weight: 600;}h2{border-bottom: 1px solid #d8dee4; padding-bottom: 0.3em}.article_content ul{padding-left:22px;}截至2025年12月23日收盘，普洛药业报收于16.72元，较前一交易日上涨0.66%，最新总市值为193.69亿元。该股当日开盘16.63元，最高16.89元，最低16.62元，成交额达8533.46万元，换手率为0.44%。公司近日发布公告称，控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的磷酸奥司他韦干混悬剂《药品注册证书》。该药品适用于2周龄及以上患者流感治疗及1岁以上人群流感预防。2024年中国市场规模约500万瓶，销售金额约1.6亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251223/31885246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["000739","BK0239","BK0060","BK0188"],"gpt_icon":0},{"id":"2593346042","title":"普洛药业(000739.SZ)：磷酸奥司他韦干混悬剂获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593346042","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593346042?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:17","pubTimestamp":1766477872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的磷酸奥司他韦干混悬剂《药品注册证书》。磷酸奥司他韦的活性代谢产物(奥司他韦羧酸盐)是选择性的流感病毒神经氨酸酶抑制剂，能够抑制甲型和乙型流感病毒的神经氨酸酶活性，通过抑制病毒从被感染的细胞中释放，减少甲型或乙型流感病毒的播散。磷酸奥司他韦干混悬剂用于2周龄及以上年龄患者的甲型和乙型流感治疗和1岁及以上年龄人群的甲型和乙型流感预防。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"普洛药业(000739.SZ)：磷酸奥司他韦干混悬剂获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0239","000739","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770626723512,"stockEarnings":[{"period":"1week","weight":0.0234},{"period":"1month","weight":0.1416},{"period":"3month","weight":0.2337},{"period":"6month","weight":0.2232},{"period":"1year","weight":0.2967},{"period":"ytd","weight":0.1549}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"普洛药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41333人(较上一季度减少19.66%)","perCapita":"28016股","listingDate":"1997-05-09","address":"浙江省金华市东阳市横店江南路399号","registeredCapital":"115844万元","survey":" 普洛药业股份有限公司的主营业务是原料药中间体、创新药研发生产服务（CDMO）、药品等研发、生产和销售以及进出口贸易业务。公司的主要产品是头孢系列、青霉素系列、精神类系列、心脑血管类系列、兽药原料药中间体系列、研发服务、商业化人用药项目、商业化兽药项目、其他项目、抗感染类、心脑血管类、精神类、抗肿瘤类。","listedPrice":5.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"普洛药业,000739,普洛药业股票,普洛药业股票老虎,普洛药业股票老虎国际,普洛药业行情,普洛药业股票行情,普洛药业股价,普洛药业股市,普洛药业股票价格,普洛药业股票交易,普洛药业股票购买,普洛药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"普洛药业(000739)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供普洛药业(000739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}